Thermo Fisher Q3: Growth Diverges Across Businesses After a Diagnostics Sale

The headline leaves a business-mix question

Thermo Fisher Scientific’s October 21 results show revenue of $12.14 billion for the quarter ended September 26, up 9% from a year earlier. The company reported 6% organic revenue growth, a measure that excludes acquisitions, divestitures and currency translation. The difference matters because the business portfolio itself has changed.

The investment question is whether growth is broad enough to support expectations across the company’s operations. Our reading of the segment disclosures is more selective: some businesses show stronger underlying expansion, while another comparison is affected by a completed sale. Treating the headline as a uniform demand signal would lose that distinction.

Thermo Fisher also reported GAAP diluted earnings per share of $4.64 and adjusted EPS of $6.68. Both increased from the year-earlier quarter. Those earnings measures provide context, but they do not resolve which businesses are driving a sustainable improvement. That requires examining the segment growth bridges and the scope of the portfolio.

Use the segment bridge before extrapolating demand

The company’s financial package reports third-quarter organic growth of 1% in Life Sciences Solutions, 6% in Analytical Instruments, zero in Specialty Diagnostics and 10% in Laboratory Products and Biopharma Services. These are company-defined non-GAAP comparisons, not independent estimates of end-market demand.

The distinctions create different follow-up questions. For the faster-growing businesses, an investor should seek evidence that the improvement can persist beyond the current comparison period. For slower-growing operations, the question is whether weakness is temporary, concentrated in particular activities, or more widespread. The segment percentages alone cannot answer those questions or identify specific customer behavior.

Life Sciences Solutions illustrates the need to retain both measures: its reported growth was 5%, while organic growth was 1%. Applying the reported rate as an assumption for the existing business would combine two different sources of change. A useful research model should keep portfolio effects separate from the growth assumption used for comparable operations.

A completed sale changes the diagnostics comparison

Thermo Fisher announced on August 12 that it had completed the sale of its microbiology business to Astorg. The disclosed consideration was approximately $1.075 billion, including a $50 million seller note. Thermo Fisher said the business generated $645 million of revenue in 2025 and had belonged to Specialty Diagnostics. These are transaction-background figures, not third-quarter revenue or profit contributions.

Astorg’s own completion announcement confirms that the acquired business would operate independently. Its activities include microbiological testing products for clinical, pharmaceutical and food-safety applications. The buyer’s announcement corroborates the separation; it does not independently verify Thermo Fisher’s quarterly earnings.

The timing places the completed sale within the quarter being reported. That makes a direct comparison of the reported diagnostics revenue totals less useful as a stand-alone demand indicator. The financial package shows a negative acquisition/divestiture effect for the segment while its organic growth was flat. It would therefore be premature to interpret the reported sales decline as evidence of an equivalent deterioration in the retained business.

The reverse inference would also go too far. Flat organic growth is not evidence of accelerating demand, and the sale does not prove that the remaining portfolio will deliver better returns. Those propositions require subsequent operating evidence.

What would strengthen or weaken the interpretation

The next research step is to compare later disclosures on the same basis, preserving each segment’s reported growth, organic growth and portfolio changes. An investor should also track whether management explains improvements through recurring customer activity or through events that alter the comparison base. A change in the businesses being consolidated should remain visible in the model.

A stronger outcome would combine continued expansion in the leading segments with broader improvement in the slower operations. A weaker outcome would be a reversal in the leading businesses without evidence of recovery elsewhere. These are conditions to monitor, not forecasts derived from one quarter.

The current release supports a differentiated assessment of Thermo Fisher’s growth. Its consolidated results improved, but the segment bridges and the microbiology sale show why that improvement should not be projected evenly across the portfolio. Keeping the underlying growth question separate from the ownership change makes the next earnings comparison more informative.